Foundation Consumer Healthcare closes Plan B One-Step buy, names new CEO
PITTSBURGH — Foundation Consumer Healthcare has announced a new addition to its product offerings. The company has completed its $675 million acquisition of Plan B One-Step and two value emergency contraceptive brands from Teva. Alongside its new products, the company has added Greg Bradley, a 34-year CPG industry veteran, as its president and CEO.
“As the #1 OB/GYN recommended OTC emergency contraceptive brand and an important birth control option for women across the United States, Plan B One-Step is the perfect addition to our growing portfolio,” Bradley said. “We look forward to devoting immense resources to support Plan B One-Step and working closely with our retail partners to ensure continued access to this critical women’s health product.”
Bradley’s experience includes improving in-market performance of existing OTC healthcare brands. He has worked at GlaxoSmithKline overseeing several prescription-to-OTC switches, and founded Advantage Consumer Healthcare in 2011. Advantage Consumer Healthcare specialized in OTC switches and healthcare product launches. Foundation Consumer Healthcare said Advantage Consumer Healthcare would remain as its OTC selling partners.
Among the products marketed by Foundation Consumer Healthcare is St. Joseph Aspirin, Theravent, Neo-Synephrine, Bronkaid and Campho Phenique. The company’s senior leadership has more than 80 years of collective experience, it said.
“The senior leadership team at FCH is dedicated to supporting innovative therapies and focused on driving growth across our product portfolio,” Bradley said. “As the category leader, Plan B One-Step plays an important role in women’s health, and FCH is eager to invest the resources and thinking necessary to help Plan B One-Step fulfill that role.”
Pfizer promotes Bourla to COO
Pfizer names COO
NEW YORK — Pfizer has named Albert Bourla COO, effective Jan. 1, 2018. The promotion of Bourla, who was most recently group president of the company’s Innovative Health business, is accompanied by the promotion of two others within the company. John Young will take over Bourla’s vacated position and Angela Hwang will the role of Pfizer Essential Health group president role left open by Young’s promotion, both effective Jan. 1, 2018.
“Albert is a proven and trusted leader with over two decades of leadership experience and a demonstrated track record for delivering strong business results,” Pfizer chairman Ian Read said. “He possesses the right combination of skills, knowledge, strengths and a deep commitment to Pfizer’s culture that make him the clear choice to become Pfizer’s COO.”
Under Bourla, who took the helm in 2016, Pfizer Innovative Health saw 11% operational growth in 2016 and 9% growth in the first nine months of 2017. Before heading that division, Bourla was group president of Pfizer’s vaccine, oncology and consumer healthcare businesses. His other roles at Pfizer have included work as an area president for its animal health business in the Europe, Africa and Asia Pacific regions, where he oversaw the integration of Wyeth’s animal health business with Pfizer’s in those markets.
"The addition of a COO will enable me to spend more time focusing on the company's long-term strategic direction, ensuring continued R&D productivity and engaging with government policy and industry leaders on key issues facing the future of the healthcare industry,” Bourla said.
Taking the helm at Pfizer’s Innovative Health Division is Young, who has held such positions at the company as president of its primary care business. He will move to Innovative Health from his position as group president of the Essential Health business, which will be filled by Hwang.
Hwang is the company’s global president and general manager for Pfizer inflammation and immunology. She has been with the company since 2007 and has held such positions as regional head for U.S. vaccines, vice president of U.S. brands business within Essential Health and vice president of emerging markets within the primary care business. Both Hwang and Young will report to Bourla.
Hyland’s brings new items to the sleeping aids market
Hyland’s has introduced three products to the sleeping aids category, with company officials hopeful that there is more demand for products in the growing category.
According to Les Hamilton, the Los Angeles-based company’s president, consumers are looking for a wide range of products from the category. “It’s beyond sleep,” he said. “It’s a holistic approach to relaxation [with] essential oils, candles, aromatherapy. It’s a different mindset now from ‘I’ve got to take a pill to get to sleep.’”
Hyland’s new products — Rest, Calm and Awaken — are designed to help combat sleeplessness and stress, as well as offer an energy boost. It’s the kind of three-pronged comprehensive solution set more consumers are looking for that helps users sleep at night, get back to alertness when they wake up and keeps them stress-free through the day, Hamilton added.
The sleep category first got a jolt from the introduction of Procter & Gamble’s ZzzQuil sleeping aids in 2012 that lifted the category from the floor of its analgesic adjacency to eye-level, both literally and figuratively.
Today that category is producing an annual growth rate of about 5% to $739.6 million in sales across total U.S. multi-outlets for the 52 weeks ended Sept. 10, according to IRI.